GlassScriptPhysician profile
Frieda Goldman
NPI 1841270329
$6,017.65
in general payments reported to CMS, 2019-2025
28 companies · $898 in 2025
The $898 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $837 · 2020: $665 · 2021: $806 · 2022: $920 · 2023: $983 · 2024: $908 · 2025: $898.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,709 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,709.37 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,298.84 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $847.75 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $560.32 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $430.09 | 2019-2024 | Xarelto |
| Pfizer INC. | $392.13 | 2019-2025 | |
| Lilly USA, LLC | $330.30 | 2020-2025 | Mounjaro, Jardiance |
| Astellas Pharma US INC | $309.87 | 2019-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $245.78 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $232.52 | 2020-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Kowa Pharmaceuticals America, INC. | $190.64 | 2019-2023 | Seglentis, Livalo |
| Takeda Pharmaceuticals U.S.A., INC. | $190.48 | 2019-2023 | Trintellix |
| Merck Sharp & Dohme LLC | $180.27 | 2019-2024 | Vaxneuvance, Vaqta, Vaxelis |
| Exact Sciences Corporation | $165.39 | 2023-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $134.55 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $112.86 | 2024-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $88.72 | 2019-2024 | Repatha, Otezla |
| Allergan, INC. | $75.01 | 2019-2020 | |
| Amarin Pharma, INC. | $54.74 | 2019-2021 | |
| Bausch Health US, LLC | $32.77 | 2022-2023 | Aplenzin, Wellbutrin |
| Nestle Healthcare Nutrition INC. | $29.55 | 2021 | |
| Biogen, INC. | $19.19 | 2023 | Spinraza |
| Agios Pharmaceuticals, INC. | $17.17 | 2025 | Pyrukynd |
| Sanofi Pasteur INC. | $15.00 | 2019 | |
| Kedrion Biopharma, INC. | $13.86 | 2024 | Rhogam Ultra-Filtered Plus, Albuked, Kedrab |
| Avanir Pharmaceuticals, INC. | $13.42 | 2021 | |
| Ibsa Pharma INC. | $13.00 | 2020 | |
| Alexion Pharmaceuticals, INC. | $12.39 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $11.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frieda Goldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.